Abbisko Therapeutics discovers and develops small‑molecule precision‑oncology and immuno‑oncology drugs that target validated oncogenic drivers and immune pathways, such as CSF‑1R, FGFR4, KRAS G12D, EGFR C797S, PD‑L1 and CXCR4. Leveraging an in‑house multi‑dimensional R&D platform that integrates cancer genomics, medicinal chemistry and biomarker science, the company advances a pipeline of over ten oral candidates, with several in clinical stages, through monotherapy and combination trials for solid tumors and rare diseases in China and globally.
Funding
$123M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OTCFounders
Product
Problem
Patients with various cancers and rare diseases often lack targeted small‑molecule therapies that can address specific oncogenic drivers or immune pathways, leading to limited treatment options and suboptimal outcomes, especially in China and other underserved markets.
Solution
Abbisko Therapeutics discovers and develops differentiated small‑molecule drugs that precisely inhibit validated oncogenic targets (e.g., CSF‑1R, FGFR4, KRAS G12D, EGFR C797S) and modulate tumor‑immune interactions (e.g., oral PD‑L1, CXCR4 inhibitors). Its in‑house, multi‑dimensional R&D platform integrates cancer genomics, computational chemistry, and biomarker science to generate high‑quality candidates efficiently. The company advances a pipeline of more than ten programs, with five already in clinical stages, and conducts both monotherapy and combination trials to improve efficacy and overcome resistance. Global clinical development capabilities and strategic partnerships enable rapid progression from IND to market across China and internationally.
Target Audience
Primary customers are pharmaceutical companies and oncology clinicians seeking novel, orally administered targeted therapies for solid tumors and rare diseases, as well as biotech partners interested in co‑development or licensing of precision‑oncology and immuno‑oncology assets.
Features
- Robust in‑house discovery engine combining genomics, medicinal chemistry, and translational biomarker expertise.
- Portfolio of precision‑oncology small molecules targeting CSF‑1R, FGFR4/2/3, KRAS G12D, EGFR C797S, PRMT5, and immune targets such as PD‑L1 and CXCR4.
- Clinical‑stage programs include monotherapy and combination regimens (e.g., FGFR4 inhibitor with atezolizumab, PD‑L1 inhibitor with EGFR inhibitor).
- IND‑enabled pipeline with IND approvals from NMPA, FDA, and EMA for multiple candidates.
- Global out‑licensing and partnership model to leverage external R&D and commercial expertise.
- Focus on oral, small‑molecule formats to provide favorable safety, dosing convenience, and combination flexibility.